ArticleJournal of nanobiotechnology2025
Ultrasound-activated and P-selectin-targeted liposomes overcome biofilm barriers for surgical site infections therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Pseudomonas aeruginosa-induced biofilm-associated surgical site infections (BSSIs) pose a dual therapeutic challenge: the dense extracellular polymeric substances (EPS) barriers hinder drug enrichment and penetration, whereas the immunosuppressive microenvironment within the biofilm impedes infection clearance, leading to persistent bacterial colonization and recurrence. This study developed an ultrasound-activated P-selectin-targeted liposome (SPCMPL) integrating natural sulfatide ligands (targeting P-selectin overexpressed in inflamed BSSI vasculature), sonosensitizer chlorin e6 (Ce6), meropenem prodrug, and perfluoropentane (PFP) to achieve efficient antibiotic delivery and BSSI treatment via breaking through the biofilm barriers and activating immunomodulation. SPCMPL employed ligand/receptor-mediated transcytosis for enrichment in BSSI lesions, where the PFP phase transition triggered by ultrasound disrupted the biofilm EPS structure. This process can both trigger the in-situ generation of reactive oxygen species (ROS) by Ce6 and loosen the EPS matrix. This degradation then facilitated meropenem release, allowing it to penetrate the biofilm more effectively and achieve antimicrobial concentrations throughout. Furthermore, the mass-produced ROS polarized macrophages to a pro-inflammatory M1 phenotype, thereby enhancing phagocytosis, remodeling the microenvironment, and inhibiting biofilm persistence. Ultrasound-triggered spatial control localized antibiotic release and immunomodulation to the infection site, optimizing local delivery while minimizing systemic toxicity and reducing the risk of systemic cytokine storms. The results demonstrated that the SPCMPL with ultrasound manipulation integrated biofilm disruption, targeted drug release, and immunomodulation to completely eradicate both planktonic and biofilm-embedded bacteria and effectively treat BSSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.